Chinese Scientist Ostracized Over Gene-Edited Babies Seeks Comeback
By Liyan Qi and Jonathan Cheng,
The Wall Street Journal
| 03. 26. 2025
photo via Wikimedia Commons licensed under CC by 3.0
Chinese scientist He Jiankui set off global outrage and landed in prison after he skirted ethical guidelines and claimed he had produced genetically modified babies designed to resist HIV infection.
Now, the self-styled gene editing pioneer is trying to stage a comeback with another controversial project, aiming to use gene editing to prevent Alzheimer’s disease in future generations.
One monumental hurdle: gaining the trust of a scientific community that treats him as a pariah.
International media has dubbed him “China’s Frankenstein.” He has no academic affiliations. He declines to reveal where his funding comes from or who his backers are. It isn’t helping that he won’t repudiate his controversial approach. On March 11, He posted on X that “Ethics is holding back scientific innovation and progress.”
At his Beijing home in a gated compound, a relaxed He outlined his plans for a scientific comeback. He can’t travel—he said China won’t renew his passport—but hopes to send two Chinese colleagues to the U.S. to conduct research on mice and monkeys for the Alzheimer’s project...
Related Articles
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Dan Falk, Nautilus | 08.20.2026
The pseudoscience of eugenics, founded on the mistaken notion that nature envisions some “right” combination of genes, and that selective breeding can improve the human race, is making a comeback. While the heyday of eugenics was a century ago, the...
By Emily Packard Dawson and Lainie Friedman Ross, MedPage Today | 08.18.2026
Few things evoke a greater sense of desperation than a parent seeking an experimental treatment for their child. That desperation can make even extraordinary risks seem worth taking. This dynamic has come into stark relief after Mei, a 6-year-old girl...
By Ryan Cross, Endpoints News | 08.20.2026
China’s cheap, fast and quiet system for testing cutting-edge medicines is facing scrutiny after the deaths of three people in investigator-initiated trials.
The studies, also known as IITs, allow experimental cell and gene therapies to be tested without oversight from...